{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/fungal-nail-infection/","result":{"data":{"firstChapter":{"id":"bc563964-f1b0-559d-9f21-380162710ddf","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field e1fc2bfb-40c3-4b36-b77b-51c398690513 --><h1>Fungal nail infection: Summary</h1><!-- end field e1fc2bfb-40c3-4b36-b77b-51c398690513 -->","htmlStringContent":"<!-- begin item f4660b91-5760-4ccc-9024-a76eed10b9b9 --><!-- begin field 9f197e66-cf47-4ed4-a6a1-560de7be0a96 --><ul><li>Fungal nail infection (onychomycosis) can involve any part of the nail, or the entire nail unit including the nail plate, nail bed, and root of the nail.<ul><li>The nail unit may discolour, the nail plate distort, and the nail bed and adjacent tissue may thicken.</li><li>Toenails are seven times more likely to be affected than fingernails.</li></ul></li><li>Infection is caused by dermatophyte and non-dermatophyte moulds, and yeasts such as <em>Candida</em> species. Dermatophytes are responsible for about 90% of cases.</li><li>Fungal nail infection is more common in older people and is rare in children.</li><li>Risk factors for infection include concomitant fungal skin infection; psoriasis; diabetes mellitus, peripheral arterial disease, immunocompromised states; repeated nail trauma, and occlusive footwear.</li><li>Fungal nail infection should be suspected if:<ul><li>The nail looks abnormal and is discoloured.</li><li>There are white or yellow streaks along one side of the nail.</li><li>There is thickening of the nail; white or yellow spots; or complete destruction of the nail.</li><li>There is associated paronychia, which may suggest Candida infection.</li></ul></li><li>Assessment of suspected fungal nail infection should include:<ul><li>Asking about symptoms such as pain and discomfort; difficulty wearing footwear and walking; psychosocial impact; any co-morbidities or risk factors for infection; any family or household members affected.</li><li>Classifying the type of onychomycosis, if possible.</li><li>Examining for fungal skin infection at other sites.</li><li>Arranging nail clippings and/or scrapings for fungal microscopy and culture to confirm the diagnosis and underlying cause, if the person wishes to start antifungal treatment.</li></ul></li><li>Initial management of fungal nail infection should include advice on:<ul><li>Self-care strategies, such as keeping nails short; wearing non-occlusive footwear; and treating associated tinea pedis.</li><li>The option of topical antifungal treatment, such as amorolfine nail lacquer, if there is early, limited, or superficial dermatophyte or Candida nail infection.</li></ul></li><li>If initial measures are not successful or appropriate, management with oral antifungal agents may be indicated:<ul><li>Terbinafine may be used first-line for confirmed dermatophyte infection.</li><li>Itraconazole may be used first-line for confirmed Candida or non-dermatophyte infection (off-label).</li><li>Griseofulvin may be considered if terbinafine or itraconazole are contraindicated.</li><li>Nail regrowth should be assessed 3–6 months after the start of treatment.</li></ul></li><li>If there are signs of treatment failure, the following measures can be considered:<ul><li>Managing any underlying cause.</li><li>Re-sampling for nail clippings and/or scrapings for fungal microscopy and culture. </li><li>Combination treatment with a topical and oral antifungal agent.</li></ul></li><li>Referral to a podiatrist may be considered if:<ul><li>Thickened toenails cause discomfort when walking.</li><li>There is nail trauma due to the person's footwear.</li><li>Deformed toenails are traumatizing adjacent toes.</li></ul></li><li>Referral to a dermatologist may be considered if:<ul><li>Oral antifungal treatment is being considered for a child.</li><li>The diagnosis is uncertain.</li><li>Treatment in primary care is unsuccessful.</li><li>There is co-existent nail disease, such as psoriasis or lichen planus.</li><li>The person is immunocompromised, depending on clinical judgement.</li></ul></li></ul><!-- end field 9f197e66-cf47-4ed4-a6a1-560de7be0a96 --><!-- end item f4660b91-5760-4ccc-9024-a76eed10b9b9 -->","topic":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151","topicId":"d2c6135f-fef1-4a56-80dc-161c93380c7d","topicName":"Fungal nail infection","slug":"fungal-nail-infection","aliases":[],"chapters":[{"id":"bc563964-f1b0-559d-9f21-380162710ddf","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"dd347390-fb63-5e80-9fab-bd3cc4704341","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"0cdd100c-c9d0-5685-980c-52f246d1100e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"886d32db-68df-5055-b459-55404c1f011e","slug":"changes","fullItemName":"Changes"},{"id":"c1cacd2b-dba0-5341-a274-66fd882b2036","slug":"update","fullItemName":"Update"}]},{"id":"9f0a65a3-9309-5a00-a9fa-bda2fb7a49c4","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"1121797b-5555-5e24-a9ae-aabc657725dd","slug":"goals","fullItemName":"Goals"},{"id":"aa660497-e222-5e9d-b282-3069500c380f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49df22af-d1aa-56cd-b2dc-30e6ecc84ca8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a79a5fd4-4f6a-5d37-8714-e4bd3bea76b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6db25a8b-db82-5b72-bade-fa216c349fd8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2515b15e-47ac-5e93-acaf-588daa2e06f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d257da5b-218f-50fc-96b1-55ec4b44f5cd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"7ccd879d-9979-5f0b-b655-8da37ca04149","slug":"definition","fullItemName":"Definition"},{"id":"20d20421-b2ba-513f-87b5-3fad4f731aa5","slug":"causes","fullItemName":"Causes"},{"id":"3142330a-0287-5835-8a69-857972828fb2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"29b083db-9488-5407-92df-43f4952d8df3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d7dd4e0b-6a97-5db7-bfa3-aa690c7974af","slug":"complications","fullItemName":"Complications"},{"id":"3a29be3f-ea9f-56a3-b8d7-78341665856e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4346dd42-e5eb-550e-a004-7c8e7103a196","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"b6a7486c-a6d8-5d8b-918c-8610bf76e212","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"eec0a81e-c0c0-5f9d-951e-f19c41cfafaf","slug":"assessment","fullItemName":"Assessment"},{"id":"d84aa70d-b236-5783-9eeb-e1181b1311f8","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","slug":"management","fullItemName":"Management","subChapters":[{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine"},{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"0b102b3a-ebce-5c6e-9670-3610defc871d","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"bc0bd4bc-1b10-52dc-b942-cd4682774d01","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"dc202e28-37b1-5789-a14a-b5a0850d8cf8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49993e8c-ae7a-5891-bf43-21a6406ce1b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b6aa45b7-d833-599f-8bcc-4d08c6c264bb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2805cbb7-09b5-5875-a0c1-c501223c6ab3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"595745a2-d654-5e3b-850e-eac6532bd5db","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74af204e-7571-5d05-963f-0c0614335fbf","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151","topicId":"d2c6135f-fef1-4a56-80dc-161c93380c7d","topicName":"Fungal nail infection","slug":"fungal-nail-infection","aliases":[],"topicSummary":"Fungal nail infection (onychomycosis) can involve the nail plate, nail bed, and/or the root of the nail. It affects toenails more frequently than the","lastRevised":"Last revised in March 2018","nextPlannedReviewBy":"2023-03-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2023-03","nextPlannedReviewByDisplay":"March 2023","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"bc563964-f1b0-559d-9f21-380162710ddf","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"dd347390-fb63-5e80-9fab-bd3cc4704341","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"0cdd100c-c9d0-5685-980c-52f246d1100e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"886d32db-68df-5055-b459-55404c1f011e","slug":"changes","fullItemName":"Changes"},{"id":"c1cacd2b-dba0-5341-a274-66fd882b2036","slug":"update","fullItemName":"Update"}]},{"id":"9f0a65a3-9309-5a00-a9fa-bda2fb7a49c4","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"1121797b-5555-5e24-a9ae-aabc657725dd","slug":"goals","fullItemName":"Goals"},{"id":"aa660497-e222-5e9d-b282-3069500c380f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49df22af-d1aa-56cd-b2dc-30e6ecc84ca8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a79a5fd4-4f6a-5d37-8714-e4bd3bea76b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6db25a8b-db82-5b72-bade-fa216c349fd8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2515b15e-47ac-5e93-acaf-588daa2e06f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d257da5b-218f-50fc-96b1-55ec4b44f5cd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"7ccd879d-9979-5f0b-b655-8da37ca04149","slug":"definition","fullItemName":"Definition"},{"id":"20d20421-b2ba-513f-87b5-3fad4f731aa5","slug":"causes","fullItemName":"Causes"},{"id":"3142330a-0287-5835-8a69-857972828fb2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"29b083db-9488-5407-92df-43f4952d8df3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d7dd4e0b-6a97-5db7-bfa3-aa690c7974af","slug":"complications","fullItemName":"Complications"},{"id":"3a29be3f-ea9f-56a3-b8d7-78341665856e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4346dd42-e5eb-550e-a004-7c8e7103a196","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"b6a7486c-a6d8-5d8b-918c-8610bf76e212","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"eec0a81e-c0c0-5f9d-951e-f19c41cfafaf","slug":"assessment","fullItemName":"Assessment"},{"id":"d84aa70d-b236-5783-9eeb-e1181b1311f8","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","slug":"management","fullItemName":"Management","subChapters":[{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine"},{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"0b102b3a-ebce-5c6e-9670-3610defc871d","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"bc0bd4bc-1b10-52dc-b942-cd4682774d01","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"dc202e28-37b1-5789-a14a-b5a0850d8cf8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49993e8c-ae7a-5891-bf43-21a6406ce1b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b6aa45b7-d833-599f-8bcc-4d08c6c264bb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2805cbb7-09b5-5875-a0c1-c501223c6ab3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"595745a2-d654-5e3b-850e-eac6532bd5db","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74af204e-7571-5d05-963f-0c0614335fbf","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151"}},"staticQueryHashes":["3666801979"]}